FDA warned Mile High Compounds that it sells unapproved injectable GLP-1-like drugs and BAC water online.
What happened
FDA reviewed the company’s website and linked community forum from January to March 2026. FDA found offers for GLP-1 SM, GLP-2 TRZ, GLP-3 RT, and BAC Water for sale in the U.S., with labeling and cheat sheets describing human uses such as weight loss and weekly dosing despite research-only statements. FDA determined the products are unapproved new drugs.
What FDA found
FDA says these are unapproved new drugs—products that need an FDA-approved application before sale across state lines—and no such approvals exist.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)FDA says website and forum materials show the products are intended for human use, including weight loss and weekly dosing, despite “research only” labels.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128FDA says BAC Water is a drug because it is sold with peptide products intended for injection and reconstitution.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of steps taken to correct the violations, how it will prevent recurrence, and related documents. If it believes there is no violation or cannot finish corrections in time, it must explain and give a completion timeframe.
Who should pay attention
- compounding pharmacies and peptide sellers marketing injectable products
- brands and suppliers that sell or ship research-labeled peptides
- consumers buying GLP-1-like peptides online
This is a summary. Read the original letter on fda.gov.